The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a broader reassessment of the medical devices sector, Needham has maintained its Buy rating for Boston Scientific (BSX) while significantly lowering its price target from $77.00 to $57.00. According to reports, this adjustment by analyst Mike Matson reflects a more cautious outlook despite the firm's overall positive stance. Notably, insider buying activity exceeding $0.5 million has been recorded, signaling strong management confidence in the company's long-term trajectory.
This target revision occurs as valuation metrics highlight a significant disconnect; GuruFocus data suggests a GF Value of $105.65, implying the stock is undervalued by approximately 57.1% relative to its current trading price. While peers like Medtronic and Stryker face similar sectoral headwinds regarding operational costs, Boston Scientific’s perceived intrinsic value remains high per market data, supported by consistent insider accumulation during this period of price consolidation.
BSX shares stood at $44.6 at close on July 06, 2026, remaining well below the revised $57.00 target. Traders are currently monitoring the recent low of $43.84 as a key technical support level. With no major upcoming economic catalysts specifically tied to the medical technology sector in the immediate seven-day calendar, market attention will likely remain focused on internal corporate developments and further insider transaction signals.